Substance
ID:73926
Names and Identifiers
Synonyms
Ozagrel
IUPAC Traditional name
(2E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic acid
IUPAC name
(2E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]prop-2-enoic acid
Registration numbers
CAS Number
Properties
Safety Information
Storage Condition
-20°C
Product Information
Salt Data
Free Base
Molecule Details
Research Area: Cardiovascular Disease
Biological Activity:
Ozagrel is a potent and selective thromboxane A2 synthetase inhibitor with an IC50 of 4 nM. It does not inhibit prostacyclin (PGI2) synthetase, cyclooxygenase or PGE2 isomerase (IC50 > 1 mM). Inhibits platelet aggregation in vitro and arachidonate-induced arterial contraction in vivo. The beneficial effects of TXAS inhibition by ozagrel include improved motor coordination after experimental stroke and antihypertensive effects in spontaneously hypertensive rats. [1][2][3]References on Ozagrel[1] http://en.wikipedia.org/wiki/Ozagrel, , [2] Jpn J Pharmacol., 1986 Jul, 41(3):393-401.[3] J Urol., 1987 Mar, 137(3):571-6.
Biological Activity:
Ozagrel is a potent and selective thromboxane A2 synthetase inhibitor with an IC50 of 4 nM. It does not inhibit prostacyclin (PGI2) synthetase, cyclooxygenase or PGE2 isomerase (IC50 > 1 mM). Inhibits platelet aggregation in vitro and arachidonate-induced arterial contraction in vivo. The beneficial effects of TXAS inhibition by ozagrel include improved motor coordination after experimental stroke and antihypertensive effects in spontaneously hypertensive rats. [1][2][3]References on Ozagrel[1] http://en.wikipedia.org/wiki/Ozagrel, , [2] Jpn J Pharmacol., 1986 Jul, 41(3):393-401.[3] J Urol., 1987 Mar, 137(3):571-6.
Molecular Spectra
No Data Available
Click here to submit data
References
• Loo MH et al. J Urol. 1987 Mar;137(3):571-6